Gómez Mediavilla Borja, Lanza-León Paloma, Martínez Callejo Virginia, Cantarero-Prieto David, Lanza Postigo María, Salcedo Lambea Matilde, Blanco Mesonero Yolanda, Ochagavia Sufrategui María, Durán Ignacio, Sarabia Cobo Carmen María
Medical Oncology and Nanovaccines Research Gruop, Instituto de Investigación Valdecilla-IDIVAL, Santander, Spain.
Departamento de Economía, Universidad de Cantabria, Santander, Spain; Health Economics Research Group, Valdecilla Biomedical Institute Research - IDIVAL, Santander, Spain.
Biomed J. 2024 Apr 27;48(2):100742. doi: 10.1016/j.bj.2024.100742.
The aim of this study was twofold: to assess the annual pharmaceutical savings associated with the treatment of cancer patients at Marqués de Valdecilla University Hospital and to estimate the cost of innovative antineoplastic therapies that patients receive as experimental treatment, both during clinical trials throughout 2020.
An observational and financial analysis of the drug cost related to clinical trials was applied. Direct cost savings to the Regional Health System of Cantabria and the cost of innovative therapies used as an experimental treatment in clinical trials were quantified.
This study includes 38 clinical trials with a sample of 101 patients. The clinical trials analyzed provide a total cost savings of €603,350.21 and an average cost saving of €6630.22 per patient. Furthermore, the total investment amounts to €789,892.67, with an average investment of €15,488.09 per patient.
Clinical trials are essential for the advancement of science. Furthermore, clinical trials can be a significant source of income for both hospitals and Regional Health Systems, contributing to their financial sustainability.
本研究有两个目的：评估与马尔克斯·德·巴尔德西利亚大学医院癌症患者治疗相关的年度药品节省情况，并估算2020年全年临床试验期间患者作为试验性治疗接受的创新抗肿瘤疗法的费用。
对与临床试验相关的药品成本进行观察性和财务分析。量化了坎塔布里亚地区卫生系统的直接成本节省以及在临床试验中用作试验性治疗的创新疗法的成本。
本研究包括38项临床试验，样本为101名患者。分析的临床试验总共节省成本603,350.21欧元，每位患者平均节省成本6630.22欧元。此外，总投资为789,892.67欧元，每位患者平均投资15,488.09欧元。
临床试验对科学进步至关重要。此外，临床试验可以成为医院和地区卫生系统的重要收入来源，有助于其财务可持续性。
